Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial

Trials

Michael Hutchinson²  Niall Tubridy²  Christopher McGuigan²  Jennifer Brady⁵  Cathal Walsh⁷  Jean Fletcher³  Lorraine Cassidy⁸  Carmel McKenna¹  Donal O’Shea⁴  Risteard O’Laoide⁶  Eric Heffernan⁶  David Murphy⁶  Orla Kenny²  Sinead Jordan²  Katie Kinsella²  Siobhan Kelly²  Karen O’Connell² 

[1] Pharmacy Department, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland;Department of Neurology, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland;Schools of Medicine and Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Pearse Street, Trinity College Dublin, Dublin 2, Ireland;Department of Endocrinology, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland;Department of Biochemistry and Diagnostic Endocrinology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland;Department of Radiology, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland;Department of Statistics, Trinity College Dublin, Dublin 2, Ireland;Consultant Ophthalmologist and Occuloplastic Surgeon, Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Ireland

关键词: Clinical trial;    Cholecalciferol;    Immunomodulation;    Multiple sclerosis;    Clinically isolated syndrome;    Vitamin D;   

Others  :  1093163
DOI  :  10.1186/1745-6215-14-272

 received in 2013-05-01, accepted in 2013-08-08,  发布年份 2013

【 摘 要 】

Background

There is increasing evidence linking vitamin D deficiency to both susceptibility to, and severity of, multiple sclerosis (MS). Patients with the clinically isolated syndrome represent the initial presentation of a demyelinating disorder, and those with asymptomatic lesions on magnetic resonance imaging (MRI) are at risk of progression to clinically definite MS. The aims of this study are to examine the immunologic effects of vitamin D in both healthy individuals and in patients with clinically isolated syndrome, and in the latter group the effects on disease progression assessed by MRI and clinical measures.

Methods/Design

This is a single-center double-blind randomized placebo-controlled clinical trial. The primary endpoint is the immunologic effects of two doses of vitamin D compared with placebo over 24 weeks in both healthy control participants and patients presenting with the clinically isolated syndrome. Healthy control participants (n = 39) and patients with clinically isolated syndrome (n = 45) will be randomized to one of three arms, namely 1) vitamin D 5,000 IU daily, 2) vitamin D 10,000 IU daily, or 3) placebo, and followed up for 24 weeks. In both patients and healthy control participants, the primary outcome will be immunologic measures of the frequency of CD4 T-cell subsets and cytokine responses in peripheral blood mononuclear cells, assessed at baseline, and after 16 and 24 weeks of treatment. Secondary endpoints, in the patients with clinically isolated syndrome, will be relapse activity, and the number of new T2 lesions and gadolinium-enhancing lesions assessed by MRI in the two vitamin D-treated groups compared with the placebo-treated group over the 24 weeks of the study.

Trial registration

EU Clinical Trials Register: EudraCT: 2012-000635-68. ClinicalTrials.gov identifier: NCT01728922

【 授权许可】

   
2013 O’Connell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ebers G: Environmental factors and multiple sclerosis. Lancet Neurol 2008, 7:268-277.
• [2]Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B: Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82(10):1132-1141.
• [3]Ramagopalan SV, Handel AE, Giovannoni G, Rutherford Siegel S, Ebers GC, Chaplin G: Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011, 76:1410-1414.
• [4]Orton SM, Wald L, Confavreux C, Vukusic S, Krohn JP, Ramagopalan SV, Herrera BM, Sadovnick AD, Ebers GC: Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011, 76:425-431.
• [5]Dean G: Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. BMJ 1967, 2:724-730.
• [6]Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, McCall MG: The epidemiology of multiple sclerosis in 3 Australian cities: Perth, Newcastle and Hobart. Brain 1988, 111:1-25.
• [7]Van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ: Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007, 254:581-590.
• [8]Hill TR, Flynn A, Kiely M, Cashman KD: Prevalence of suboptimal vitamin D status in young, adult and elderly Irish subjects. Ir Med J 2006, 99(2):48-49.
• [9]Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, Hagan R, Duggan M, Jordan S, McKenna M, Hutchinson M, Tubridy N: Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 2011, 82:317-322.
• [10]Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I: A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:152-157.
• [11]Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R: Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008, 14(9):1220-1224.
• [12]Mowry E, Krupp L, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E: Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010, 67:618-624.
• [13]Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I: Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010, 68:193-203.
• [14]Mirzaei F, Michels KB, Munger K, O’Reilly E, Chitnis T, Forman MR, Giovannucci E, Rosner B, Ascherio A: Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 2011, 70:30-40.
• [15]Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P: Vitamin D as a protective factor in multiple sclerosis. Neurology 2012, 79:2140-2145.
• [16]Dobson R, Giovannoni G, Ramagopalan S: The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry 2012, 84(4):427-432.
• [17]Goldberg P, Fleming MC, Picard EH: Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986, 21:193-200.
• [18]Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
• [19]Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch D-M, Cheung R, Gagne D, D’Souza C, Ursell M, O’Connor P: A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859.
• [20]The IFNB: multiple sclerosis study group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43(4):655-661.
• [21]PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 35(9139):1498-1504.
• [22]Correale J, Ysrraelit MC, Gaitán MI: Immunomodulatory effects of vitamin D in MS. Brain 2009, 132:1146-1160.
• [23]Adorini L, Penna G: Control of immune diseases by the vitamin D endocrine system. Nature Clin Pract Rheumat 2008, 4:404-412.
• [24]Bhalla AK, Amento EP, Serog B, Glimcher LH: 1,25-dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984, 133:1748-1754.
• [25]Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE: Modulatory effects of 1,25- dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
• [26]Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A: 1alpha,25- Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
• [27]Dörr J, Ohlraun S, Skarabis H, Paul F: Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012, 13:15. BioMed Central Full Text
• [28]Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M, Beelke M: SOLAR study group: efficacy of vitamin d3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011, 311(1–2):44-49.
• [29]Hutchinson M, Zajicek J: Clinically isolated syndrome: a protected zone for trials of new therapies? Mult Scler 2010, 16:754-755.
• [30]GraphPad http://www.graphpad.com/quickcalcs/randomize1.cfm webcite
• [31]Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin F, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson A, Waubant E, Weinshenker B, Wolinsky J: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302.
• [32]Allen AC, Kelly S, Basdeo SA, Kinsella K, Mills KHG, Tubridy N, Walsh C, Brady J, Hutchinson M, Fletcher JM: A pilot study of the immunological effects of high dose vitamin D in healthy volunteers. Mult Scler 2012, 18(12):1797-1800.
• [33]Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society: Evaluation, treatment and prevention of vitamin D deficiency. An endocrine society clinical practice guideline. 2011, 96:1911-30.
• [34]Vieth R: Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 2006, 136:1117-1122.
• [35]Vieth R, Kimball S, Hu A, Walfish PG: Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004, 3:1-8. BioMed Central Full Text